Progyny, Inc. (PGNY) AI Stock Analysis

Progyny, Inc., headquartered in New York, New York, is a benefits management company that delivers fertility and family-building solutions for employers across the United States. Founded in 2008 and formerly known as Auxogyn, Inc., the company offers tailored plan designs covering specialized fertility care. Its offerings include concierge-style member support services and access to a curated network of fertility specialists. Progyny also operates Progyny Rx, an integrated pharmacy benefits solution providing medications for fertility treatments, as well as employer reimbursement programs for surrogacy and adoption.

Progyny expanded annual revenue from $500.6M in FY2021 to $1.29B in FY2025, representing a 5-year revenue CAGR of 30.2%. Gross margin improved to 23.6% in FY2025 from 21.7% in FY2024, while operating margin rose to 6.6%. Annual net income reached $58.5M in FY2025 with diluted EPS of $1.26. For the trailing twelve months ended June 30, 2026, revenue stood at $1.31B with an operating margin of 11.4% and EPS of $0.92. In the latest quarter ended June 30, 2026, quarterly revenue grew 5.3% year-over-year, while quarterly earnings surged 78.9%.

As of June 30, 2026, Progyny held $236.9M in cash and short-term investments against $27.0M in total debt, yielding a net cash position of $210.0M. The company reported a current ratio of 2.14 and a debt-to-equity ratio of 0.06 on shareholders' equity of $453.3M. In FY2025, operating cash flow reached $210.2M and free cash flow was $191.8M. Capital expenditures totaled $18.4M in FY2025, while share buybacks consumed $81.7M, contributing to an 18.1% decline in share count over 5 years.

At $26.86 per share, Progyny trades at a trailing P/E of 29.2x, above the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 11.8x sits below the peer median of 17.3x, while its EV/EBITDA of 15.0x compares to the peer median of 12.0x. The company has a price-to-sales multiple of 1.6x, compared to the peer median of 4.1x. Over the past year, the stock returned 25.9%, outperforming the S&P 500 return of 16.8%, but over 5 years its return of -52.0% lagged the S&P 500 return of 83.0%.

Wall Street analysts covering Progyny maintain 9 Strong Buy, 1 Buy, and 2 Hold recommendations, with no Sell or Strong Sell ratings. The mean price target is $34.42, representing an upside of 28.1% from the last close of $26.86. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.38B and EPS of $2.08. Progyny beat earnings estimates in each of the last 4 quarters, and its next earnings report is scheduled for November 5, 2026.

This page is an AI-written research summary of Progyny, Inc. (PGNY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PGNY income statement, PGNY balance sheet, PGNY key metrics, PGNY analyst forecast, PGNY chart. See the PGNY stock overview for the latest quote and news.